Redeye Feed

2025-09-12 16:21:00 Biovica Q1 Update - Capitalised but the launch is still not in full swing

2025-09-11 10:46:00 Redeye Initiates Coverage of Guard Therapeutics

2025-09-09 13:13:00 BioArctic - Strong momentum, fair price

2025-09-09 13:10:00 Litium - More Brains, More Geins

2025-09-04 11:06:00 Redeye Initiates Coverage of Senzime

2025-09-04 11:05:00 Sprint Bioscience - A clear objective to secure a new partner

2025-09-03 16:11:00 Flexion Mobile - Building growth momentum

2025-09-02 10:35:00 Dala Energi - All eyes on the NAV

2025-09-02 10:34:00 Mindark - Sequential sales rebound

2025-09-02 10:33:00 Integrum Q1 - Miss on sales

2025-09-02 10:31:00 Heliospectra - Momentum building, but larger greenhouse projects still ahead

2025-09-02 10:29:00 Corline Biomedical - Kardium receives FDA approval

2025-09-01 11:16:00 Elicera Q2 - Developing CARMA – Data strengthens ELC-301 outlook

2025-09-01 11:15:00 Insplorion - Large follow-up order in the pipeline

2025-09-01 11:14:00 Nekkar - Q2 Review – Postponed Recovery

2025-09-01 11:13:00 IRLAB Therapeutics Q2 - Focus on value creation following strengthened financials

2025-09-01 11:12:00 Systemair - Ready for more M&A

2025-08-29 12:54:00 Jumpgate Q2 2025 - Additions to the project pipeline

2025-08-29 12:52:00 GiG Software - Strengthened balance sheet and focus on larger clients

2025-08-29 12:51:00 Lytix Biopharma Q2 2025 - Extended Update

2025-08-29 12:51:00 Fable Media Group - Dividend Season, Four Times a Year

2025-08-28 17:09:00 FluoGuide Q2 2025 - Gearing up for the next phase

2025-08-28 17:08:00 Lipum Q2 - Focus on securing funding

2025-08-28 10:34:00 Redeye Initiates Coverage of BICO Group

2025-08-28 10:32:00 GomSpace Q2 Review - Orbiting Higher

2025-08-28 10:31:00 Smart Eye - On the Autobahn to 2026

2025-08-28 10:30:00 AcouSort Q2 - Robust cost control

2025-08-27 17:07:00 Faron Pharmaceuticals H1 - Advancing to registrational trials

2025-08-27 12:35:00 BioInvent Q2 2025 - Narrowed Focus on BI-1206 and BI-1808

2025-08-27 11:58:00 AlzeCure Q2 - Prepares for clinical studies

2025-08-27 11:56:00 Xbrane Biopharma Q2 2025 - Important months ahead

2025-08-27 11:55:00 Gentoo Media - Another weak quarter, but potential for recovery in H2

2025-08-27 11:54:00 Corline Biomedical Q2 - Kardium’s Globe system nearing launch

2025-08-26 14:28:00 Lipigon Q2 2025 - Last Patient In

2025-08-26 14:27:00 Isofol Medical Q2 - Refueled by a strengthened cash position

2025-08-26 14:26:00 Neola Medical Q2 - Potential share price trigger incoming

2025-08-25 16:40:00 Active Biotech Q2 2025 - On the Eve of a Laquinimod Deal

2025-08-25 16:39:00 IDL Diagnostics - Still under the radar

2025-08-25 11:27:00 Egetis Therapeutics Q2 - Great US and European progress

2025-08-25 11:26:00 Sleep Cycle - Headwinds in the short-term, momentum in strategic initiatives

2025-08-25 11:25:00 Cantargia Q2 2025 - Major Deal and Negative TRIFOUR Readout

2025-08-25 11:24:00 I-Tech - Q2 Review – Temporary Slowdown

2025-08-25 11:23:00 Navigo Q2 2025 - Ready for a turnaround

2025-08-25 11:22:00 AVTECH - No room for turbulence

2025-08-25 11:21:00 InfraCom - A crucible of confidence

2025-08-25 11:20:00 CLS Q2 - Strong report that reinforces confidence in outlook

2025-08-25 11:19:00 Acarix Q2 - An eventful quarter

2025-08-22 17:42:00 Medivir Q2 2025 - Awaiting Phase IIb

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Redeye

Prenumeration

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden